Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

G Paz

Showing results (161-170 of 188) with videos related to

Pageof 19
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 13, 2020
Phase I Study of the Efficacy and Safety of Ramucirumab in Combination with Osimertinib in Advanced T790M-positive <i>EGFR</i>-mutant Non-small Cell Lung CancerHelena A Yu, Luis G Paz-Ares, James Chih-Hsin Yang, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 31, 2010
Molecular analysis of non-small cell lung cancer identifies subsets with different sensitivity to insulin-like growth factor I receptor inhibitionAntonio Gualberto, Marisa Dolled-Filhart, Mark Gustavson, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 10, 2013
PARAMOUNT: Final overall survival results of the phase III study of maintenance pemetrexed versus placebo immediately after induction treatment with pemetrexed plus cisplatin for advanced nonsquamous non-small-cell lung cancerLuis G Paz-Ares, Filippo de Marinis, Mircea Dediu, et al.
Molecular Biology Reports|June 28, 2025
The rs3757385 polymorphism increases IRF5 expression and systemic nitric oxide metabolites, protecting urothelial bladder cancer patients from recurrenceAriane P Souza, Isabely M Silva, Beatriz G L Vacario, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|June 5, 2025
Treatment-Free Survival Over 6 Years of Follow-up in Patients With Metastatic NSCLC Treated With First-Line Nivolumab Plus Ipilimumab Versus Chemotherapy in CheckMate 227 Part 1Solange Peters, Meredith M Regan, Luis G Paz-Ares, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|September 12, 2009
Safety, pharmacokinetics, and pharmacodynamics of the insulin-like growth factor type 1 receptor inhibitor figitumumab (CP-751,871) in combination with paclitaxel and carboplatinDaniel D Karp, Michael N Pollak, Roger B Cohen, et al.
Lung Cancer (Amsterdam, Netherlands)|December 2, 2017
Treatment outcomes by histology in REVEL: A randomized phase III trial of Ramucirumab plus docetaxel for advanced non-small cell lung cancerLuis G Paz-Ares, Maurice Pérol, Tudor-Eliade Ciuleanu, et al.
Cancer Discovery|October 10, 2020
Precision Prevention and Cancer Interception: The New Challenges of Liquid BiopsyMaria Jose Serrano, Maria Carmen Garrido-Navas, Juan Jose Diaz Mochon, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 8, 2018
Abemaciclib in Combination with Single-Agent Options in Patients with Stage IV Non-Small Cell Lung Cancer: A Phase Ib StudyEdward S Kim, Karen Kelly, Luis G Paz-Ares, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 2, 2012
Phase III, randomized, double-blind, placebo-controlled trial of gemcitabine/cisplatin alone or with sorafenib for the first-line treatment of advanced, nonsquamous non-small-cell lung cancerLuis G Paz-Ares, Bonne Biesma, David Heigener, et al.
Pageof 19

Showing results (161-170 of 188) with videos related to

Sort By:
Pageof 19
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 13, 2020
Phase I Study of the Efficacy and Safety of Ramucirumab in Combination with Osimertinib in Advanced T790M-positive <i>EGFR</i>-mutant Non-small Cell Lung CancerHelena A Yu, Luis G Paz-Ares, James Chih-Hsin Yang, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 31, 2010
Molecular analysis of non-small cell lung cancer identifies subsets with different sensitivity to insulin-like growth factor I receptor inhibitionAntonio Gualberto, Marisa Dolled-Filhart, Mark Gustavson, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 10, 2013
PARAMOUNT: Final overall survival results of the phase III study of maintenance pemetrexed versus placebo immediately after induction treatment with pemetrexed plus cisplatin for advanced nonsquamous non-small-cell lung cancerLuis G Paz-Ares, Filippo de Marinis, Mircea Dediu, et al.
Molecular Biology Reports|June 28, 2025
The rs3757385 polymorphism increases IRF5 expression and systemic nitric oxide metabolites, protecting urothelial bladder cancer patients from recurrenceAriane P Souza, Isabely M Silva, Beatriz G L Vacario, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|June 5, 2025
Treatment-Free Survival Over 6 Years of Follow-up in Patients With Metastatic NSCLC Treated With First-Line Nivolumab Plus Ipilimumab Versus Chemotherapy in CheckMate 227 Part 1Solange Peters, Meredith M Regan, Luis G Paz-Ares, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|September 12, 2009
Safety, pharmacokinetics, and pharmacodynamics of the insulin-like growth factor type 1 receptor inhibitor figitumumab (CP-751,871) in combination with paclitaxel and carboplatinDaniel D Karp, Michael N Pollak, Roger B Cohen, et al.
Lung Cancer (Amsterdam, Netherlands)|December 2, 2017
Treatment outcomes by histology in REVEL: A randomized phase III trial of Ramucirumab plus docetaxel for advanced non-small cell lung cancerLuis G Paz-Ares, Maurice Pérol, Tudor-Eliade Ciuleanu, et al.
Cancer Discovery|October 10, 2020
Precision Prevention and Cancer Interception: The New Challenges of Liquid BiopsyMaria Jose Serrano, Maria Carmen Garrido-Navas, Juan Jose Diaz Mochon, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 8, 2018
Abemaciclib in Combination with Single-Agent Options in Patients with Stage IV Non-Small Cell Lung Cancer: A Phase Ib StudyEdward S Kim, Karen Kelly, Luis G Paz-Ares, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 2, 2012
Phase III, randomized, double-blind, placebo-controlled trial of gemcitabine/cisplatin alone or with sorafenib for the first-line treatment of advanced, nonsquamous non-small-cell lung cancerLuis G Paz-Ares, Bonne Biesma, David Heigener, et al.
Pageof 19